At the time of writing, Amylyx Pharmaceuticals Inc [AMLX] stock is trading at $12.39, up 1.47%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The AMLX shares have gain 8.78% over the last week, with a monthly amount drifted -6.35%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Guggenheim started tracking the stock with Buy rating on June 24, 2025, and set its price target to $17. On June 17, 2025, Citigroup initiated with a Buy rating and assigned a price target of $12 on the stock. TD Cowen started tracking the stock assigning a Buy rating. Mizuho upgraded its rating to an Outperform but $7 remained the price target by the analyst firm on April 07, 2025. Robert W. Baird upgraded its rating to Outperform for this stock on November 18, 2024, and upped its price target to $11. In a note dated October 23, 2024, BofA Securities upgraded a Buy rating on this stock and boosted its target price from $4.20 to $10.
For the past year, the stock price of Amylyx Pharmaceuticals Inc fluctuated between $2.60 and $16.96. Currently, Wall Street analysts expect the stock to reach $20 within the next 12 months. Amylyx Pharmaceuticals Inc [NASDAQ: AMLX] shares were valued at $12.39 at the most recent close of the market. An investor can expect a potential return of 61.42% based on the average AMLX price forecast.
Analyzing the AMLX fundamentals
According to Amylyx Pharmaceuticals Inc [NASDAQ:AMLX], the company’s sales were -0.67M for trailing twelve months, which represents an -100.00% plunge. Gross Profit Margin for this corporation currently stands at 31.07% with Operating Profit Margin at 236.6%, Pretax Profit Margin comes in at 225.44%, and Net Profit Margin reading is 224.48%. To continue investigating profitability, this company’s Return on Assets is posted at -0.41, Equity is -0.69 and Total Capital is -0.47. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It is important to note that Amylyx Pharmaceuticals Inc [NASDAQ:AMLX] has a current ratio of 13.70. In addition, the Quick Ratio stands at 13.70 and the Cash Ratio stands at 8.73.
Transactions by insiders
Recent insider trading involved FRATES JAMES M, Chief Financial Officer, that happened on Jan 06 ’26 when 3326.0 shares were sold. Co-Chief Executive Officer, Cohen Joshua B completed a deal on Jan 06 ’26 to sell 7715.0 shares. Meanwhile, Co-Chief Executive Officer Klee Justin B. sold 7715.0 shares on Jan 06 ’26.
